Sinovac Biotech ( (SVA) ) just unveiled an announcement.
On April 1, 2025, Sinovac Biotech Ltd. announced a special cash dividend of $55.00 per common share, funded from its available cash resources. This decision follows a Privy Council court order affirming the legitimacy of the current board elected in 2018. The board is reviewing past corporate actions, including a 2018 share issuance, to ensure compliance with the order. The dividend aims to provide shareholders with their share of prior distributions from subsidiaries, with future pro-rata distributions planned.
More about Sinovac Biotech
Sinovac Biotech Ltd. is a China-based biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of vaccines for human infectious diseases. Its product portfolio includes vaccines for COVID-19, enterovirus 71, hepatitis A, varicella, influenza, poliomyelitis, and pneumococcal disease. The company has a global market presence, with its COVID-19 vaccine, CoronaVac, approved in over 60 countries.
Average Trading Volume: 8,227
Technical Sentiment Signal: Hold
Current Market Cap: $460.3M
For detailed information about SVA stock, go to TipRanks’ Stock Analysis page.